Yocca Frank 4
4 · BioXcel Therapeutics, Inc. · Filed May 7, 2026
Research Summary
AI-generated summary of this filing
BioXcel (BTAI) CSO Frank Yocca Exercises 9,000 RSUs
What Happened
Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics (BTAI), reported the vesting/conversion of 9,000 restricted stock units (RSUs) on May 1, 2026. The Form 4 shows an acquisition entry for 9,000 shares via exercise/conversion (transaction code M) and a matching disposition of 9,000 shares reported at $0.00. No cash proceeds or exercise price are reported.
Key Details
- Transaction date: May 1, 2026 (reported on Form 4 filed May 7, 2026).
- Prices/values shown: Acquisition listed as N/A; disposition listed at $0.00 (no cash proceeds reported).
- Shares owned after transaction: Not disclosed in this filing.
- Footnotes: F1 — each RSU converts to one share of common stock; F2 — these 9,000 RSUs were granted on Aug 1, 2025 and vested 100% on or within 30 days of nine months from the grant date (effectively May 1, 2026).
- Filing timeliness: The Form 4 was filed six days after the transaction date, outside the typical two-business-day reporting window.
Context
This was a derivative conversion of RSUs rather than an open-market purchase or sale. A disposition reported at $0.00 typically indicates a conversion/settlement (for example, issuance and immediate withholding/cancellation) rather than a cash sale; the filing does not specify the reason. No explicit tax-withholding or sale-for-cash details are provided, and the filing does not state resulting share ownership.
Insider Transaction Report
- Exercise/Conversion
Common Stock
[F1]2026-05-01+9,000→ 15,520 total - Exercise/Conversion
Restricted Stock Units
[F1][F2]2026-05-01−9,000→ 0 total→ Common Stock (9,000 underlying)
Footnotes (2)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
- [F2]On August 1, 2025 (the "Grant Date"), the Reporting Person was granted 9,000 RSUs, vesting as to 100% on or within thirty (30) days of 9 months from the Grant Date, subject to the Reporting Person's continued employment with the Issuer or a subsidiary of the Issuer on such date.